Remibrutinib (LOU064) treatment improves chronic spontaneous urticaria in patients irrespective of previous anti-IgE treatment: Phase 2b study results

被引：0

作者：

Metz, M. ^{[1
,2
,3
,4
]}

Greiner, A. ^{[5
,6
]}

Guduri, S. ^{[7
]}

Leflein, J.

Haemmerle, S. ^{[8
]}

Lheritier, K. ^{[8
]}

Walsh, P. ^{[9
]}

Nikolaev, I. ^{[8
]}

Gimenez-Arnau, A. M. ^{[10
]}

Maurer, M. ^{[1
,2
,3
,4
]}

机构：

[1] Inst Allergol, UCARE, Berlin, Germany

[2] Freie Univ, Berlin, Germany

[3] Humboldt Univ, Berlin, Germany

[4] Fraunhofer Inst Translat Med & Pharmacol ITMP, Allergol & Immunol, Berlin, Germany

[5] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA

[6] Univ Calif San Diego, San Diego, CA USA

[7] Centricity Res Inc, Columbus, OH USA

[8] Novartis Pharma AG, Basel, Switzerland

[9] Novartis Ireland Ltd, Dublin, Ireland

[10] Univ Pompeu Fabra, Dept Dermatol, Hosp Mar IMIM, Barcelona, Spain

来源：

ALLERGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

000883

引用

页码：245 / 246

页数：2

共 50 条

[1] Remibrutinib Improves Chronic Spontaneous Urticaria in Patients Irrespective of Previous Anti-IgE Treatment: Results From a Phase 2b Study
Greiner, Alexander
Guduri, Sridhar
Leflein, Jeffrey
Haemmerle, Sibylle
Lheritier, Karine
Walsh, Pauline
Nikolaev, Ivan
Gimenez-Arnau, Ana
Maurer, Marcus
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB131 - AB131
[2] Remibrutinib (LOU064) treatment improves hive severity in patients with chronic spontaneous urticaria: Findings from a Phase 2b study
Gimenez-Arnau, A. M.
Hayama, K.
Jain, V.
Sitz, K.
Lheritier, K.
Nikolaev, I.
Walsh, P.
Haemmerle, S.
Maurer, M.
ALLERGY, 2023, 78 : 245 - 245
[3] Long-term safety and tolerability of remibrutinib (LOU064) in Phase 2b study in chronic spontaneous urticaria patients
Gimenez-Arnau, A.
Maurer, M.
Metz, M.
Jain, V.
Walsh, P.
Lheritier, K.
Hugot, S.
Zouater, H.
Haemmerle, S.
Zharkov, A.
ALLERGY, 2023, 78 : 13 - 13
[4] Remibrutinib (LOU064) reduces the use of rescue medication in patients with chronic spontaneous urticaria: Findings from a Phase 2b study
Maurer, M.
Reed, J.
Staubach-renz, P.
Lheritier, K.
Walsh, P.
Meti, V.
Nikolaev, I.
Haemmerle, S.
Gimenez-Arnau, A. M.
ALLERGY, 2023, 78 : 14 - 14
[5] REMIBRUTINIB TREATMENT IMPROVES HIVE SEVERITY IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS
Sitz, K.
Gimenez-Arnau, A.
Hayama, K.
Jain, V.
Lheritier, K.
Walsh, P.
Haemmerle, S.
Maurer, M.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S11 - S11
[6] Remibrutinib Treatment Improves Itch and Sleep in Chronic Spontaneous Urticaria Patients: Phase 2b Study Results
Hsu, Connie
Snyder, Robert
Clore, Lee
Jain, Vipul
Gimenez-Arnau, Ana
Lheritier, Karine
Walsh, Pauline
Haemmerle, Sibylle
Wells, Michael
Nikolaev, Ivan
Maurer, Marcus
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB82 - AB82
[7] REMIBRUTINIB TREATMENT IMPROVES SLEEP AND ACTIVITY IN CHRONIC SPONTANEOUS URTICARIA PATIENTS: PHASE 2B STUDY RESULTS
Clore, L.
Jain, V.
Gimenez-Arnau, A.
Lheritier, K.
Walsh, P.
Haemmerle, S.
Maurer, M.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S32 - S32
[8] Remibrutinib (LOU064) showed good stability of response in patients with chronic spontaneous urticaria: A novel exploratory analysis of data from the phase 2B study
Maurer, M.
Gimenez-Arnau, A. M.
Jain, V.
Reich, A.
Ortmann, C. E.
Walsh, P.
Haemmerle, S.
ALLERGY, 2023, 78
[9] REMIBRUTINIB IMPROVES CHRONIC SPONTANEOUS URTICARIA IN PATIENTS IRRESPECTIVE OF CU-INDEX: RESULTS FROM PHASE 2B STUDY
Carr, W.
Sitz, K.
Jain, V.
Gimenez-Arnau, A.
Lheritier, K.
Nikolaev, L.
Haemmerle, S.
Maurer, M.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S11 - S11
[10] REMIBRUTINIB SHOWED GOOD STABILITY OF RESPONSE IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY
Tillinghast, J.
Jain, V.
Maurer, M.
Gimenez-Arnau, A.
Reich, A.
Ortmann, C.
Walsh, P.
Haemmerle, S.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S41 - S41

← 1 2 3 4 5 →